| Expression pattern: |
UP |
| Associated gene: |
DMPK, AGO2 |
| Associated microRNA: |
miR-409-3p |
| Biological function: |
Regulates DM1-associated molecular features; silencing reduces DMPK expression, decreases nuclear foci, and partially rescues splicing defects. |
| Molecular mechanism: |
Physical and functional interaction with miR-409-3p (co-regulation; RISC-associated); miR-409-3p overexpression counteracts effects of circARHGAP10 silencing. |
| Biological pathway or process: |
ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Sanger Sequencing; Back-Splice Junction PCR / divergent primers PCR; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Bioinformatics Analysis; Transfection; RNA Pull-Down; RIP (RNA Immunoprecipitation); FISH / smFISH; IF (Immunofluorescence); Western Blot; Annexin V/PI Flow Cytometry; ROC Analysis |
| Clinical significance: |
Correlates positively with CTG repeat length and inversely with muscle strength; circ/lin ratio shows diagnostic potential (ROC AUC 0.86) to discriminate DM1 patients from controls. |
| Description: |
circARHGAP10 is upregulated in DM1 skeletal muscle and shows biomarker potential (correlates with CTG repeat length and muscle strength; ROC AUC 0.86). Functionally, circARHGAP10 knockdown in DM1 myogenic cells reduces DMPK levels, decreases toxic nuclear RNA foci, and partially rescues missplicing, with effects mediated at least partly through interaction/co-regulation with miR-409-3p. |
| Confidence score: |
0.8635 |